Sign in
Not yet taking people in United StatesPhase 2

Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)

Key facts

Who runs it
National Cancer Institute (NCI)
Where
Bethesda, United StatesSee the site
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
50 people, planned
Starts
23 Nov 2026
Expected to end
1 Jul 2030
Type of study
Interventional
Treatments tested
  • PRGN-2012
  • Bevacizumab
Record updated
18 November 2026

Who can take part

Age
18 years to 120 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (30)Hide the full registry criteria

Who cannot take part

  • History of significant cardiovascular disease or thromboembolic event: cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure (>= New York Heart Association Classification Class II) occurring within 12 months prior to the study treatment initiation
  • Any investigational agents within 4 weeks prior to the study treatment initiation
  • Systemic medical RRP therapy within 4 weeks or 3 half-lives, whichever is longer prior to the study treatment initiation
  • Participants with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to the study treatment initiation. Note: Inhaled, topical intranasal or intraocular steroids, and adrenal replacement doses <10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
  • History of abdominal fistula or gastrointestinal perforation within 12 months prior to the study treatment initiation
  • Major surgery within 4 weeks prior to the study treatment initiation. Note: The surgery is considered major if a mesenchymal barrier is opened (pleural cavity, peritoneum, meninges)
  • History of hemoptysis (>2.5 mL of bright red blood per episode) within 1 month prior to the study treatment initiation
  • History of serious hemorrhage (CTCAE Grade 4) within 12 months prior to the study treatment initiation
  • Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to the study treatment initiation
  • Prior history of hypertensive crisis or hypertensive encephalopathy
  • Persisting toxicity related to prior therapy of Grade >1 per CTCAE. Note: Alopecia, sensory neuropathy Grade <= 2 are acceptable
  • Known, active alcohol or drug abuse
  • Serious cardiac arrhythmia requiring medication as assessed by electrocardiogram (EKG) at screening
  • Non-healing wounds, active ulcer, or untreated bone fracture
  • Evidence of bleeding diathesis or significant coagulopathy (with or without current therapeutic anticoagulation)
  • Inadequately controlled hypertension (defined as systolic blood pressure (BP) >150 mmHg and/or diastolic blood pressure > 100 mmHg). Note: an average of 3 BP readings on 2 sessions will be used to measure blood pressure if the initial reading indicates inadequately controlled hypertension. Anti-hypertensive therapy to achieve blood pressures below these parameters is allowed
  • History of allergy to study drug components
  • History of >= Grade 3 per CTCAE infusion-related reaction to bevacizumab or PRGN-2012
  • Uncontrolled symptomatic, intercurrent illness evaluated by medical history, physical exam, and labs, or social situations that would unacceptably increase risk for the participant or impair the ability to evaluate the endpoints of the study, or that would limit compliance with study requirements
  • Pregnancy confirmed with beta-human chorionic gonadotropin (beta-HCG) serum or urine pregnancy test in WOCBP at screening

Other criteria

  • INCLUSION CRITERIA:
  • Histological or cytological diagnosis of RRP confirmed by pathology report. Note: If there is no documentation or archival sample, a biopsy will be done to confirm the diagnosis
  • Age >= 18 years old
  • A history of 2 or more surgeries or use of IV bevacizumab in order to control laryngeal and/or tracheal RRP within 12 months prior to the study treatment initiation
  • Previous treatment with PRGN-2012 (zopapogene imadenovec [Papzimeos])
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • Participants must have an adequate organ and marrow function as defined below:; White blood cells (WBC) >2,000/mcL; Absolute neutrophil count (ANC) >= 1,000/mcL; Hemoglobin > 9.0 g/dL; Platelets >= 100,000/mcL; Total bilirubin <= 1.5 mg/dL. Note: participants with Gilbert s Syndrome must have a total bilirubin < 3.0 mg/dL; Aspartate aminotransferase (AST) <= 2.5 X institutional upper limit of normal (ULN); Alanine aminotransferase (ALT) <=2.5 X institutional ULN; Creatinine within normal institutional limits OR Creatinine Clearance (CrCl) >= 60 mL/min/1.73 m\^2 for participants with creatinine levels above institutional normal (calculated using the Cockcroft-Gault formula); Prothrombin time (PT) / International normalized ratio (INR) and Partial thromboplastin time (PTT) <= 1 X institutional ULN. In participants on anticoagulation, coagulation tests should be within a therapeutic range; Urinalysis Urine dipstick < 2+ proteinuria. Participants with >= 2+ proteinuria on dipstick urinalysis should undergo a 24- hour urine collection and must demonstrate <= 1g of protein in 24 hours to be eligible
  • Women of child-bearing potential (WOCBP) must agree to use a highly effective method of contraception (hormonal, intrauterine device (IUD), surgical sterilization, abstinence) for the duration of treatment and up to 6 months after completion of the study treatment; Men must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) for the duration of treatment and up to 4 months after the last dose of study drugs. We also recommend men with partners of childbearing potential ask their partners to be on highly effective birth control (hormonal, IUD, surgical sterilization). Men must not freeze or donate sperm within the same period
  • Women who are breastfeeding or plan to breastfeed must agree to discontinue breastfeeding from study treatment initiation
  • Ability of participant to understand and sign a written informed consent document

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age

Where in United States

  • National Institutes of Health Clinical CenterBethesda, United StatesContact: NIH Clinical Center Office of Patient Recruitment (OPR)Not yet recruiting

About the trial

What the trial wants to find out

Background:

Read full original descriptionShow less

Recurrent respiratory papillomatosis (RRP) is a rare disease that causes wart-like growths called papillomas to grow in the airway, most often in the voice box, windpipe, or lungs. These growths can make it hard to speak or breathe. Surgery can remove the papillomas, but they often come back. In some cases, they can become cancerous.

Objective:

This study istesting whether two treatments used together (PRGN-2012, a vaccine-based treatment and bevacizumab, a drug that affects blood vessel growth) can help control RRP and reduce the chance that papillomas will grow back.

Eligibility:

Adults aged 18 years and older may be able to join the study if they have RRP and meet certain treatment history requirements. This may include people who have previously received PRGN-2012 or bevacizumab, or people who have needed more than 2 surgeries to remove papillomas.

Design:

Before starting treatment, participants will have screening tests to make sure the study is safe for them. These tests may include a physical exam with blood and urine tests, heart function testing, imaging scans, and an endoscopy. During an endoscopy, a thin, flexible tube with a small camera will look at the inside of the nose, throat, voice box, and upper windpipe.

Participants will receive study treatment during 7 clinic visits over about 6 months. Bevacizumab is given through a vein amd PRGEN-2012 is given as an injection under the skin of the arm or leg. Participants may receive 1 or both drugs at each visit.

After completing treatmen, participants will return for 4 follow-up visits over 1 year. These visits may include repeat imaging, blood and urine tests, and other exams. After that, the study team will contact participantsby phone or email every 3 months for 2 years.

If their RRP gets worse during the follow-up period, they may be able to receive a second course of treatment using the same schedule....

The group in the trial

  • Arm 1Treatment being tested

    Participants with RRP will be given Bevacizumab and PRGN-2012

    Treatment: PRGN-2012 and Bevacizumab

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase II Study of Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)
Criteria questions
Built from NCT07756840, who can take part
Record updated
18 November 2026